CSPC Pharmaceutical Group (01093): SYS 6010 has been included by the National Medical Products Administration in China in the breakthrough therapy designation list for the treatment of patients with driver gene-negative non-squamous non-small cell lung cancer.

Zhitong Finance APP News, CSPC Pharmaceutical Group (01093) announced that SYS 6010 (the "Product") developed by the group has recently been included by the National Medical Products Administration of the People's Republic of China (the "NMPA") in the list of breakthrough therapeutic varieties, with the proposed indication being recurrent or metastatic driver gene-negative non-squamous non-small cell lung cancer that has failed prior immunotherapy and platinum-containing chemotherapy.